Biocomposites will begin distributing its NanoBone range of products in the UK. The lineup consists of NanoBone SBX Putty and NanoBone QD, which are next-generation synthetic bone grafts that provide early osteogenesis and bone formation.
NanoBone’s patented technology comprises nanostructured hydroxyapatite embedded in a silica gel matrix suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration, providing a comparable healing rate to autograft and osteoinductive properties but without the costs and complications of harvesting. NanoBone is preloaded and ready to use in a wide variety of applications to maximize flexibility and efficiency during procedures.
NanoBone is manufactured by Biocomposites GmbH, a specialist manufacturer of bone graft substitutes for use in orthopedics, spine, foot and ankle and dentistry, which Biocomposites bought last year.
Following the acquisition, Biocomposites integrated and developed the NanoBone range, aiming to serve a greater number of surgeons and patients through its global distribution network.
Dr. Walter Gerike, Managing Director of Biocomposites GmbH, said: “NanoBone is a proven technology that has already helped over 100,000 patients throughout the world. The UK is a significant market and we are very pleased to start selling our innovative range of ready-to-use products there. This development furthers Biocomposites’ position as the go-to provider for surgeons requiring advanced bone regeneration materials.”
Biocomposites will begin distributing its NanoBone range of products in the UK. The lineup consists of NanoBone SBX Putty and NanoBone QD, which are next-generation synthetic bone grafts that provide early osteogenesis and bone formation.
NanoBone's patented technology comprises nanostructured hydroxyapatite embedded in a silica gel matrix...
Biocomposites will begin distributing its NanoBone range of products in the UK. The lineup consists of NanoBone SBX Putty and NanoBone QD, which are next-generation synthetic bone grafts that provide early osteogenesis and bone formation.
NanoBone’s patented technology comprises nanostructured hydroxyapatite embedded in a silica gel matrix suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration, providing a comparable healing rate to autograft and osteoinductive properties but without the costs and complications of harvesting. NanoBone is preloaded and ready to use in a wide variety of applications to maximize flexibility and efficiency during procedures.
NanoBone is manufactured by Biocomposites GmbH, a specialist manufacturer of bone graft substitutes for use in orthopedics, spine, foot and ankle and dentistry, which Biocomposites bought last year.
Following the acquisition, Biocomposites integrated and developed the NanoBone range, aiming to serve a greater number of surgeons and patients through its global distribution network.
Dr. Walter Gerike, Managing Director of Biocomposites GmbH, said: “NanoBone is a proven technology that has already helped over 100,000 patients throughout the world. The UK is a significant market and we are very pleased to start selling our innovative range of ready-to-use products there. This development furthers Biocomposites’ position as the go-to provider for surgeons requiring advanced bone regeneration materials.”
Copy to clipboard 
